Last updated: March 8, 2026
What is the Drug Identified by NDC 24979-0722?
NDC 24979-0722 corresponds to Ibrutinib tablets (brand: Imbruvica) manufactured by Janssen Biotech. Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor used primarily for treating certain hematological malignancies such as mantle cell lymphoma, chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia, and marginal zone lymphoma.
Market Size and Adoption Trends
Market Penetration
- Major indications: CLL/SLL accounts for the majority of prescriptions. According to IQVIA data, in 2022, approximately 150,000 patients worldwide received Ibrutinib.
- Competition: Other BTK inhibitors such as Acalabrutinib (Calquence) and Zanubrutinib (Brukinsa) are notable competitors.
- Physician adoption: 75% of oncologists report prescribing Ibrutinib in at least one indication, with higher usage in mature markets (US, EU).
Geographic Breakdown
| Region |
Market Share (2022) |
Growth Rate (2022-2025) |
| United States |
60% |
4% |
| European Union |
25% |
3% |
| Rest of World |
15% |
3% |
Market Drivers
- Increasing incidence of hematologic malignancies.
- Expanding label indications, including first-line treatments.
- Growing awareness among clinicians.
- Patent exclusivity until 2027 in key markets, maintaining pricing power.
Pricing and Reimbursement Landscape
Wholesale Acquisition Cost (WAC)
- Average WAC per 30-day supply: approximately $10,000.
- Annual cost: roughly $120,000 per patient.
Payer Coverage
- Coverage differences are marginal between private insurers and Medicaid.
- Reimbursement often involves high co-insurance or prior authorizations.
Cost Trends
- Historically steady WAC; recent pressure from biosimilars or generic entrants unlikely before patent expiry.
- Post-2027, expect significant price erosion, similar to other targeted oncology therapies.
Price Projections (Next 5 Years)
| Year |
Estimated WAC per 30-day supply |
Comments |
| 2023 |
$10,000 |
Current market price |
| 2024 |
$10,000 |
No significant price change |
| 2025 |
$10,000 |
Patent protection sustains pricing |
| 2026 |
$9,800 |
Slight discounts; payers push for rebates |
| 2027 |
$8,000 |
Patent expiry; biosimilar competition begins |
Post-2027 Scenario
- Price may decline by 50% or more within 2-3 years of patent expiry.
- Biosimilar entrants could price as low as $4,000-6,000 per 30-day supply.
- Market share shifts favoring generics may accelerate access expansion.
Pharmaceutical and Generic Competition Outlook
- Biosimilars and generics are unlikely before 2027.
- Patent litigation and legal delays could extend exclusivity by 1-2 years.
- Niche formulations or new indications could sustain higher prices into the late 2020s.
Regulatory Impact
- FDA Approval Pathways: Orphan drug designations provide up to 7 years market exclusivity beyond patent life.
- Price regulation: Limited in U.S.; the EU has mechanisms for price negotiations, especially in public health systems.
Key Takeaways
- The market for Ibrutinib (NDC 24979-0722) is substantial, with steady growth driven by long-term indications.
- Current prices are approximately $10,000 per month; expect stability until patent expiry.
- Post-2027, biosimilar competition is projected to halve prices within a few years.
- Market share will depend heavily on regulatory and legal factors influencing patent protection.
- Pricing trends are stable in the near term but will decline sharply after patent expiration.
FAQs
1. How dependent is the market on patent protection for pricing?
Patent protection sustains high prices; expiring patents typically lead to rapid price reductions due to biosimilar entry.
2. What factors could delay biosimilar competition?
Patent litigation, legal challenges, and regulatory delays can extend exclusivity beyond the patent expiry date.
3. Are there any off-label uses that could influence the market?
Potential off-label indications are under investigation but currently do not significantly impact the market.
4. What is the impact of combination therapies on pricing?
Combination regimens may increase total treatment costs and market penetration but could also impact patent and reimbursement strategies.
5. How do biosimilar prices compare across regions?
In Europe, biosimilars are typically priced at 20-40% of the reference product, potentially lower than in the U.S. due to pricing regulation and negotiation.
References
- IQVIA. (2022). Oncology drug trends and market share report.
- U.S. Food and Drug Administration. (2022). Approved biosimilars and patents.
- EvaluatePharma. (2023). Oncology global market forecasts.
- European Medicines Agency. (2022). Biosimilar guidance and market data.
- FDA. (2022). Market exclusivity and orphan drug policy.[1]
[1]. Evaluation of the healthcare landscape for cancer therapies. (2023). Bloomberg New Drug Pipeline.
